CClinicalTrials.gg
Enrolling by invitationNCT05497219NIA_RVUpdated May 14, 2026

Reference Values for Videofluoroscopic Measures of Swallowing

An interventional study of Videofluoroscopic Swallowing Study (VF) in Dysphagia, Oropharyngeal, sponsored by University Health Network, Toronto. Enrolling by invitation at 5 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
580
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Dysphagia (swallowing impairment) is a serious health condition seen in many age-related disease and injury processes. Although videofluoroscopy (VF) is an international "gold standard" dysphagia diagnostic exam, there is a paucity of available normative physiologic VF reference values in healthy adults across the age span to guide interpretation of these examinations. In this project, the investigators will extend previous work on the quantitative measurement of swallowing physiology from VF examinations to establish reference values for swallowing in healthy adults, and to identify clinical decision point values for differentiating healthy swallowing across the age span from disordered swallowing in several high-risk clinical populations to study dysphagia.

Read the detailed description

Dysphagia (swallowing impairment) is a serious health condition seen in many age-related disease and injury processes. Although videofluoroscopy (VF) is an international "gold standard" dysphagia diagnostic exam, there is a paucity of available normative physiologic VF reference values in healthy adults across the age span to guide interpretation of this examination. This fundamental gap in knowledge contributes to poor agreement in the identification of swallowing impairment and its underlying mechanisms. To enable better dysphagia diagnostics, there is a critical need to establish reference values for VF swallowing measures across the healthy age span.

In a previous study, the investigators developed a rigorous method for measuring swallowing physiology from VF: the Analysis of Swallowing Physiology: Events, Kinematics and Timing (ASPEKT Method). That study led to publication of initial ASPEKT reference values from 40 young healthy adults (\<60 years) and preliminary analyses comparing data from healthy older adults and small cohorts of adults with dysphagia to these reference data.

In this project, the investigtors will:

  • validate the ASPEKT Method healthy reference values for swallowing across the adult life span; and
  • profile swallowing patho-physiology in clinical groups where dysphagia is a cause of morbidity to identify clinical decision points that can be used for diagnosis and outcome measurement.

This study will explore the following research questions:

Research Question 1: Will > 5% of healthy adult participants in a new sample show ASPEKT values outside the common reference interval calculated in a prior sample? • VF measures will be collected in a prospective sample of 280 healthy adults, controlling for sex, age, and bolus consistency. Updated reference interval boundaries for healthy swallowing will be calculated.

Research Question 2: Do specific clinical conditions present with specific patterns of swallowing pathophysiology?

  • VF measures will be prospectively collected in 3 high-risk dysphagia cohorts: adults with Parkinson Disease, Chronic Obstructive Pulmonary Disease, adults in the acute stage post-stroke. Values for these clinical cohorts will be compared to age- and sex-matched reference values from healthy participants. This will delineate swallowing impairment profiles to inform clinical decision points for diagnosis.
02

Conditions studied

  • Dysphagia, Oropharyngeal

Browse trials for

Keywords

  • Deglutition
03

In context

Deglutition Disorders

710 studies on the registry are indexed under Deglutition Disorders; 219 are open to participants now.

This study's planned enrollment of 580 is above the median of 60 across 471 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy Volunteers: no history of swallowing difficulties.
  2. Clinical cohorts: physician confirmed diagnosis of the condition of interest plus symptoms of swallowing difficult, defined as a score >/=200 on the Sydney Swallow Questionnaire.

Exclusion criteria

Exclusion Criteria:

  • cognitive communication difficulties that may hinder comprehension of the study documents
  • known allergies to latex, due to the possibility that these items will come into contact with the oral mucosa during data collection
  • current pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
580 participants (estimated)

Study arms

  • Other
    Healthy adults

    Adults aged 18 or older with no history of swallowing impairment

    Diagnostic Test: Videofluoroscopic Swallowing Study (VF)

  • Other
    Parkinson Disease

    Adults with a neurologist-confirmed diagnosis of Parkinson Disease who also report symptoms of swallowing impairment, defined as a score \>/= 200 on the Sydney Swallow Questionnaire.

    Diagnostic Test: Videofluoroscopic Swallowing Study (VF)

  • Other
    Chronic Obstructive Pulmonary Disease

    Adults with a respirologist-confirmed diagnosis of Chronic Obstructive Pulmonary Disease who also report symptoms of swallowing impairment, defined as a score \>/= 200 on the Sydney Swallow Questionnaire.

    Diagnostic Test: Videofluoroscopic Swallowing Study (VF)

  • Other
    Acute Stroke

    Adult inpatients in the acute stage post stroke who are referred for swallowing assessment.

    Diagnostic Test: Videofluoroscopic Swallowing Study (VF)

Interventions

  • Diagnostic testVideofluoroscopic Swallowing Study (VF)

    A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.

06

What researchers measure

Primary outcomes

  1. Number of participants with unsafe swallowing

    Swallowing safety requires the ability to protect the airway to prevent penetration-aspiration (the entry of food or liquid material into the airway during swallowing). Swallowing safety will be measured using the Penetration-Aspiration Scale, an 8-point categorical scale which captures the depth to which any material enters the airway and whether or not the material is ejected. Levels 1 and 2 on the scale are considered safe, while levels \> 2 are considered unsafe. Actual scale scores (1-8) will be recorded and then converted to binary categorical scores (\< 3 vs \>/= 3). The frequency (count) of participants showing scores \> 2 will be reported by bolus consistency (thin, slightly thick, mildly thick, moderately thick and extremely thick liquids).

    Time frame: Baseline

  2. Number of participants with impaired swallowing efficiency

    Swallowing efficiency requires the ability to move a bolus of food or liquid from the mouth through the pharynx into the esophagus in a single swallow without leaving residue behind in the pharynx. Residue is material remaining behind in the pharynx after the swallow. Residue will be measured by tracing the area of barium visible on a lateral view x-ray (in pixels, using ImageJ software) and dividing that area by the squared length of the C2-C4 cervical spine. This cervical spine scalar provides a common anatomical reference that is a proxy for pharyngeal size, and enables the comparison of residue severity across different people with different neck length and pharynx size. In healthy swallowing, residue is expected to be minimal, i.e. less than 1% (C2-4)squared. The frequency (count) of participants showing residue above this threshold will be reported by bolus consistency (thin, slightly thick, mildly thick, moderately thick and extremely thick liquids).

    Time frame: Baseline

  3. Number of participants with delayed airway closure ("Time-to-laryngeal-vestibule-closure")

    Swallowing safety requires the ability to protect the airway to prevent penetration-aspiration (the entry of food or liquid material into the airway during swallowing). Closure of the entrance to the airway ("laryngeal vestibule closure" or LVC) must be achieved in a timely manner. Time-to-LVC will be measured, i.e., the time interval between onset of the pharyngeal swallow (i.e. onset of the hyoid burst movement) and the first frame showing the most-complete closure of the laryngeal vestibule. In healthy adults, the upper limits (97.5th percentile value) for this measure are currently reported to be 267 ms on thin liquids, 367 ms on slightly thick liquids, 367 ms on mildly thick liquids, 300 ms on moderately thick liquids and 267 ms on extremely thick liquids. The frequency (count) of participants displaying time-to-LVC measures above these limits will be reported by bolus consistency (thin, slightly thick, mildly thick, moderately thick and extremely thick liquid).

    Time frame: Baseline

  4. Number of participants with poor pharyngeal constriction

    Efficient clearance of a bolus of food or liquid through the pharynx in swallowing requires constriction of the pharynx. In healthy adults, there is typically no unobliterated space visible in the pharynx on a lateral view x-ray image on the frame of maximum constriction. ImageJ software will be used to measure the area of unobliterated pharyngeal space, which is expressed as a % of an anatomical reference scalar defined as the squared length of the C2-C4 cervical spine \[%(C2-4)squared\]. Larger unobliterated area reflects impairment in pharyngeal constriction. In healthy adults, the upper limits (97.5th percentile) for this measure are currently reported to be 6.2%(C2-4)squared on thin, 5% on slightly thick, 7.5% on mildly thick, 4.9% on moderately thick and 3.8% on extremely thick liquids. The frequency (count) of participants with pharyngeal constriction area above these limits will be reported by bolus consistency.

    Time frame: Baseline

07

Study locations

5 sites
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45221, United States
  • The Ohio State University
    Columbus, Ohio 43212, United States
  • McMaster University
    Hamilton, Ontario, Canada
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
08

References and documents

Publications

  • Yu D, Mancopes R, Milne H, Peladeau-Pigeon M, Boyce K, Chan H, Folsom M, Abrams SW, Namasivayam-MacDonald AM, Plowman EK, Steele CM. The Dynamics of Pharyngeal Shortening in Healthy Swallowing: Effects of Sex, Age, Bolus Volume and Consistency. J Oral Rehabil. 2026 Jul 6. doi: 10.1111/joor.70257. Online ahead of print. PubMed 42409758 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05497219
Lead sponsor
University Health Network, Toronto
Collaborators
University of Florida, McMaster University, National Institute on Aging (NIA), Ohio State University, University of Cincinnati
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Nov 15, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Catriona M Steele, PhD
principal investigator · University Health Network, Toronto
Emily K Plowman, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion